Literature DB >> 27202154

Treatments for EGFR Mutation-Positive (M+) NSCLC Patients - A Network Meta-Analysis (NMA) by Mutation Type.

S Popat1, J Lungershausen2, I Griebsch2, A Marten3, Y L Wu4.   

Abstract

Entities:  

Year:  2014        PMID： 27202154     DOI： 10.1016/j.jval.2014.08.2166

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  2 in total

1.  Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.

Authors:  Yi Zhao; Jingting Liu; Xiuyu Cai; Zhenkui Pan; Jun Liu; Weiqiang Yin; Hanzhang Chen; Zhanhong Xie; Hengrui Liang; Wei Wang; Zhihua Guo; Shen Zhao; Wenhua Liang; Jianxing He
Journal:  BMJ       Date:  2019-10-07

Review 2.  Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-Mutated NSCLC Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis.

Authors:  Sik-Kwan Chan; Horace Cheuk-Wai Choi; Victor Ho-Fun Lee
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.